Bibliography: library/10665-360869

The reference for library/10665-360869 (who-iris) and any references extracted from it. library · All references.

Export these 43 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

43 shown

  1. World Health Organization (2022). Guidelines on long-acting injectable cabotegravir for HIV prevention. World Health Organization.
    10665-360869 · catalogue · link · repository record · ISBN 9789240054097 (electronic version) · source: catalogue/records/10665-360869.dc.json · held: library/10665-360869
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 (https://apps.who.int/iris/handle/10665/186275, accessed 18 May 2022).
    · extracted · link · source: references/10665-360869.sec-036.1.json
  3. Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340190, accessed 18 May 2022).
    · extracted · link · source: references/10665-360869.sec-036.2.json · held: library/10665-340190
  4. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 18 May 2022).
    · extracted · link · source: references/10665-360869.sec-036.3.json
  5. 2021 UNAIDS Global AIDS Update — Confronting inequalities — Lessons for pandemic responses from 40 years of AIDS. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/en/resources/documents/2021/2021-global-aids-update, accessed 27 June 2022).
    · extracted · link · source: references/10665-360869.sec-036.4.json
  6. United Nations General Assembly. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2021 (https://www.unaids.org/sites/default/files/media_asset/2021_political-declaration-on-hiv-and-aids_en.pdf, accessed 27 June 2022).
    · extracted · link · source: references/10665-360869.sec-036.5.json
  7. Schaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8:e502-e10.
    · extracted · source: references/10665-360869.sec-036.6.json
  8. Dubov A, Ogunbajo A, Altice FL, Fraenkel L. Optimizing access to PrEP based on MSM preferences: results of a discrete choice experiment. AIDS Care. 2019;31:545-53.
    · extracted · source: references/10665-360869.sec-036.7.json
  9. Kuteesa MO, Quaife M, Biraro S, Katumba KR, Seeley J, Kamali A et al. Acceptability and predictors of uptake of anti-retroviral pre-exposure prophylaxis (PrEP) among fishing communities in Uganda: a cross-sectional discrete choice experiment survey. AIDS Behav. 2019;23:2674-86.
    · extracted · source: references/10665-360869.sec-036.8.json
  10. Minnis AM, Atujuna M, Browne EN, Ndwayana S, Hartmann M, Sindelo S et al. Preferences for long‐acting Pre‐Exposure prophylaxis (PreP) for HIV prevention among South African youth: results of a discrete choice experiment. J Int AIDS Soc. 2020;23:e25528.
    · extracted · source: references/10665-360869.sec-036.9.json
  11. Minnis AM, Browne EN, Boeri M, Agot K, Van Der Straten A, Ahmed K et al. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80:394.
    · extracted · source: references/10665-360869.sec-036.10.json
  12. Quaife M, Eakle R, Cabrera Escobar MA, Vickerman P, Kilbourne-Brook M, Mvundura M et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Making. 2018;38:120-33.
    · extracted · source: references/10665-360869.sec-036.11.json
  13. Vickerman P, Quaife M, Kilbourne-Brook M, Mvundura M, Eakle R, Terris-Prestholt F. HIV prevention is not all about HIV–using a discrete choice experiment among women to model how the uptake and effectiveness of HIV prevention products may also rely on pregnancy and STI protection. BMC Infect Dis. 2020;20:1-11.
    · extracted · source: references/10665-360869.sec-036.12.json
  14. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399:1779-89. Erratum in: Lancet. 2022 May 7;399(10337):1778. PMID: 35378077.
    · extracted · source: references/10665-360869.sec-036.13.json
  15. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608.
    · extracted · source: references/10665-360869.sec-036.14.json
  16. FDA approves first injectable treatment for HIV pre-exposure prevention [press release]. Washington (DC): U.S. Food and Drug Administration; 2021 (https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention, accessed 27 June 2022).
    · extracted · link · source: references/10665-360869.sec-036.15.json
  17. WHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
    · extracted · link · source: references/10665-360869.sec-036.16.json
  18. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A et al. Going from evidence to recommendations. BMJ. 2008;336:1049-51.
    · extracted · source: references/10665-360869.sec-036.17.json
  19. Ahluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898.
    · extracted · source: references/10665-360869.sec-036.18.json
  20. HIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
    · extracted · source: references/10665-360869.sec-036.19.json
  21. Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15:e1002690.
    · extracted · source: references/10665-360869.sec-036.20.json
  22. Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV. 2017;4:e331-e40.
    · extracted · source: references/10665-360869.sec-036.21.json
  23. Landovitz R, Donnell D, Kallas E, Magnus M, Marzinke M. Updated efficacy, safety, and case studies in HPTN 083: CAB-LA vs. TDF/FTC For PrEP. Conference on Retroviruses and Opportunistic Infections (CROI); virtual, 2022.
    · extracted · source: references/10665-360869.sec-036.22.json
  24. Dimitrov D. Population impact of expanding PrEP coverage by offering long-acting injectable cabotegravir as PrEP: Model comparison analysis. Unpublished.
    · extracted · source: references/10665-360869.sec-036.23.json
  25. Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L et al. Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083. J Infect Dis. 2021;224:1581-92.
    · extracted · source: references/10665-360869.sec-036.24.json
  26. HIV drug resistance database [website]. Menlo Park (CA): Stanford University; 2022 (https://hivdb.stanford.edu/, accessed 27 June 2022).
    · extracted · link · source: references/10665-360869.sec-036.25.json
  27. Meyer-Rath G. Cost-effectiveness modelling. Unpublished.
    · extracted · source: references/10665-360869.sec-036.26.json
  28. Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA et al. Hormonal contraception use and cabotegravir pharmacokinetics in HIV-uninfected women enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020;85:93. Guidelines on long-acting injectable cabotegravir for HIV prevention
    · extracted · source: references/10665-360869.sec-036.27.json
  29. Glaubius RL, Hood G, Penrose KJ, Parikh UM, Mellors JW, Bendavid E et al. Cost-effectiveness of injectable preexposure prophylaxis for HIV prevention in South Africa. Rev Infect Dis. 2016;63:539-47.
    · extracted · source: references/10665-360869.sec-036.28.json
  30. Quaife M, Terris‐Prestholt F, Eakle R, Cabrera Escobar MA, Kilbourne‐Brook M, Mvundura M et al. The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa. J Int AIDS Soc. 2018;21:e25064.
    · extracted · source: references/10665-360869.sec-036.29.json
  31. Smith JA, Garnett GP, Hallett TB. The potential impact of long-acting cabotegravir for HIV prevention in South Africa: a mathematical modeling study. J Infect Dis. 2021;224:1179-86.
    · extracted · source: references/10665-360869.sec-036.30.json
  32. van Vliet MM, Hendrickson C, Nichols BE, Boucher CA, Peters RP, van de Vijver DA. Epidemiological impact and cost‐effectiveness of providing long‐acting pre‐exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019;22:e25427.
    · extracted · source: references/10665-360869.sec-036.31.json
  33. Vogelzang M, Terris-Prestholt F, Vickerman P, Delany-Moretlwe S, Travill D, Quaife M. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. J Acquir Immune Defic Syndr. 2020;84:173-81.
    · extracted · source: references/10665-360869.sec-036.32.json
  34. Walensky RP, Jacobsen MM, Bekker L-G, Parker RA, Wood R, Resch SC et al. Potential clinical and economic value of long-acting preexposure prophylaxis for South African women at high-risk for HIV infection. J Infect Dis. 2016;213:1523-31.
    · extracted · source: references/10665-360869.sec-036.33.json
  35. Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M et al. Cost-effectiveness of long-acting injectable HIV preexposure prophylaxis in the United States: a cost-effectiveness analysis. Ann Intern Med. 2022;175:479-89.
    · extracted · source: references/10665-360869.sec-036.34.json
  36. Ahmed K, Baeten JM, Beksinska M, Bekker L-G, Bukusi EA, Donnell D et al. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet. 2019;394:303-13.
    · extracted · source: references/10665-360869.sec-036.35.json
  37. Luo R, Fong Y, Boeras D, Jani I, Vojnov L. The clinical impact of point-of-care infant diagnosis for HIV: a systematic review and meta-analysis. Lancet. 2022. In review.
    · extracted · source: references/10665-360869.sec-036.36.json
  38. Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10:1263.
    · extracted · source: references/10665-360869.sec-036.37.json
  39. National Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent males - a sub-study of HPTN 083. Identifier: NCT04692077. (2020, February – 2023, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04692077, accessed 18 May 2022).
    · extracted · link · source: references/10665-360869.sec-036.38.json
  40. National Institute of Allergy and Infectious Diseases (NIAID). Safety, tolerability and adolescent females - a sub-study of HPTN 084. Identifier: NCT04824131. (2020, November – 2024, May). Washington (DC): National Institutes of Health, U.S. National Library of Medicine; 2020 (https://www.clinicaltrials.gov/ct2/show/NCT04824131, accessed 18 May 2022).
    · extracted · link · source: references/10665-360869.sec-036.39.json
  41. WHO handbook for guideline development, 2nd ed. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/145714, accessed 17 February 2022).
    · extracted · link · source: references/10665-360869.sec-037.1.json
  42. HIV Modelling Consortium Working Group on Modelling Integrase Inhibitor Drug Resistance in Relation to Injectable Long-acting Cabotegravir Use in Sub-Saharan Africa. Predicted effects of introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. In preparation.
    · extracted · source: references/10665-360869.sec-037.2.json
  43. Ahluwalia AK, Inzaule S, Baggaley RB, Vitoria M, Rodolph M, Schaefer R et al. Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for pre-exposure prophylaxis. AIDS. 2022;36(13):1897-1898. For more information, contact: World Health Organization Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes 20, avenue Appia 1211 Geneva 27 Switzerland Email: hiv-aids@who.int www.who.int/hiv
    · extracted · link · source: references/10665-360869.sec-037.3.json